Research Topics
Species | J RosenstockSummaryAffiliation: Dallas Diabetes and Endocrine Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetesJ Rosenstock
Dallas Diabetes and Endocrine Center, Dallas, TX 75230, USA
Diabetes Obes Metab 8:650-60. 2006....
The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trialJulio Rosenstock
Corresponding author Julio Rosenstock
Diabetes Care 36:498-504. 2013....
Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetesJulio Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX 75230, USA
Postgrad Med 124:14-20. 2012..To evaluate the efficacy and safety of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes...- Initial combination therapy with metformin plus colesevelam in drug-naïve Hispanic patients with early type 2 diabetesJulio Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX 75230, USA
Postgrad Med 124:7-13. 2012..To evaluate initial combination therapy with metformin plus colesevelam in drug-naïve Hispanic patients with type 2 diabetes mellitus. Research.. - Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetesJulio Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, USA
Diabetes Care 35:1232-8. 2012..To evaluate the effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in type 2 diabetes mellitus inadequately controlled with metformin monotherapy... - Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapyJulio Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA
Diabetes Care 35:1473-8. 2012..To examine the safety and efficacy of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, added on to pioglitazone in type 2 diabetes inadequately controlled on pioglitazone... - Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trialJoseph C Arezzo
Albert Einstein College of Medicine, New York, NY, USA
BMC Neurol 8:33. 2008..We evaluated the efficacy of pregabalin 600 mg/d (300 mg dosed BID) versus placebo for relieving DPN-associated neuropathic pain, and assessed its safety using objective measures of nerve conduction (NC)... - AIR Inhaled Insulin System: a novel insulin-delivery system for patients with diabetesJulio Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, 7777 Forest Lane C 685, Dallas, TX 75230, USA
Expert Rev Med Devices 4:683-92. 2007..The purpose of this article is to describe the AIR Inhaled Insulin System, provide an overview of other insulin-delivery systems and discuss future strategies for the treatment of diabetes... - SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetesJulio Rosenstock
Dallas Diabetes and Endocrine Center, Dallas, Texas, USA
Diabetes Care 31:2169-76. 2008..The purpose of this study was to assess the glucose-lowering efficacy and safety of rimonabant monotherapy in drug-naive type 2 diabetic patients... - Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agentsJulio Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, USA
Diabetes Care 31:2177-82. 2008.... - Comparison of standard (self-directed) versus intensive patient training for the human insulin inhalation powder (HIIP) delivery system in patients with type 2 diabetes: efficacy, safety, and training measuresJulio Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas 75230, USA
Diabetes Technol Ther 9:80-8. 2007..Cambridge, MA) Inhaled Insulin System] was designed to be easy to use. Training methods were compared in insulin-naive patients with type 2 diabetes... - Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetesJulio Rosenstock
Dallas Diabetes and Endocrine Center, Dallas, Texas, USA
Diabetes Care 31:1723-8. 2008..The purpose of this study was to evaluate the 2-year pulmonary safety of inhaled human insulin (Exubera [EXU]) in 635 nonsmoking adults with type 2 diabetes... - Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetesJ Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX 75230, USA
Diabetes Obes Metab 10:376-86. 2008..The aim of this study was to evaluate the safety and efficacy of dose ranges of the DPP-4 inhibitor saxagliptin (BMS-477118) in patients with T2DM... - A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetesJ Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, 7777 Forest Lane C 685, Dallas, TX 75230, USA
Diabetologia 51:408-16. 2008.... - Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetesJ Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA
Diabetes Obes Metab 10:862-73. 2008..To assess the efficacy and tolerability of early combination therapy with rosiglitazone (RSG) and glimepiride (GLIM) vs. GLIM monotherapy in patients with type 2 diabetes mellitus (T2DM)... - A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patientsJulio Rosenstock
Dallas Diabetes and Endocrine Center, Dallas, Texas 75230, USA
Diabetes Care 30:1480-6. 2007.... - Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapyJulio Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX 75230, USA
Diabetes Care 31:20-5. 2008.... - Reflecting on type 2 diabetes prevention: more questions than answers!J Rosenstock
Dallas Diabetes and Endocrine Center, Medical City, Dallas, TX 75230, USA
Diabetes Obes Metab 9:3-11. 2007..These characteristics, combined with a low risk of hypoglycaemia, weight neutrality and what appears - so far - to be a relatively benign tolerability profile, make these agents intriguing candidates for preventive treatment... - Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitusJulio Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas 75230, USA
Curr Opin Endocrinol Diabetes Obes 14:98-107. 2007..To review recent clinical trials of oral dipeptidyl peptidase-4 inhibitors and examine their role in managing type 2 diabetes mellitus... - Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitusJ Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas 75230, USA
Diabetes Obes Metab 11:571-8. 2009..To assess the long-term safety and the sustained glycaemic control of vildagliptin compared with rosiglitazone over 2-year treatment in drug-naïve type 2 diabetes mellitus patients... - Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetesJ Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA
Diabet Med 28:464-9. 2011..This study assessed the efficacy and safety of PF-734200 at dose rates of 20 and 30 mg/day in subjects with Type 2 diabetes mellitus inadequately controlled on metformin monotherapy... - Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetesJulio Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, USA
Diabetes Care 33:2406-8. 2010..To assess the efficacy and tolerability of alogliptin plus pioglitazone for initial combination therapy in drug-naïve type 2 diabetic patients... - Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetesJulio Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, USA
Endocr Pract 16:629-40. 2010..To evaluate the efficacy and safety of initial combination therapy with metformin plus colesevelam in patients with early type 2 diabetes... - Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trialJulio Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX 75230, USA
Lancet 375:2244-53. 2010..We aimed to assess the efficacy and safety of prandial Technosphere inhaled insulin compared with twice daily biaspart insulin... - Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetesJulio Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, USA
Diabetes Care 33:1173-5. 2010..To assess the effects of exenatide on body weight and glucose tolerance in nondiabetic obese subjects with normal or impaired glucose tolerance (IGT) or impaired fasting glucose (IFG)... - Safety and efficacy of inhaled human insulin (exubera) during discontinuation and readministration of therapy in adults with type 2 diabetes: a 3-year randomized controlled trialJulio Rosenstock
Dallas Diabetes and Endocrine Center, Texas 75230, USA
Diabetes Technol Ther 11:697-705. 2009..New York, NY] (insulin human [recombinant DNA origin]) inhalation powder} in adults with type 2 diabetes (T2DM)... - Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemiaJ Rosenstock
Dallas Diabetes and Endocrine Center, Dallas, TX 75230, USA
Diabetes Obes Metab 11:1145-52. 2009..To assess the efficacy and safety of alogliptin added to insulin in patients with type 2 diabetes inadequately controlled with insulin alone or combined with metformin... - Redefining insulin therapy in type 2 diabetes mellitusJulio Rosenstock
Dallas Diabetes and Endocrine Center, 7777 Forest Lane C 618, Dallas, Texas 75230, USA
Postgrad Med 116:21-9. 2004.... - IntroductionJulio Rosenstock
Dallas, Texas 75230, USA
Postgrad Med 116:3. 2004..This lack of appreciation may represent a missed opportunity to arrest or slow disease progression... - Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetesJ Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, 7777 Forest Lane, C 685, Dallas, TX 75230, USA
Curr Med Res Opin 25:2401-11. 2009..To evaluate the efficacy and safety of once-daily saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes (T2D) and inadequate glycemic control... - Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label studyJ Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, 7777 Forest Lane C 685, Dallas, TX, 75230, USA
Diabetologia 52:1778-88. 2009..This long-term study was designed to further characterise the retinal safety profile of insulin glargine and human neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes mellitus... - Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trialJulio Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, 7777 Forest Lane, Dallas, TX 75230, USA
Diabetes Care 30:217-23. 2007..To compare the efficacy and tolerability of vildagliptin and rosiglitazone during a 24-week treatment in drug-naïve patients with type 2 diabetes... - Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic controlJ Rosenstock
Dallas Diabetes and Endocrine Center, Dallas, TX 75230, USA
Diabetes Obes Metab 8:643-9. 2006.... - Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetesJulio Rosenstock
Dallas Diabetes and Endocrine Center, Medical City Dallas, 7777 Forest Lane, Suite C 618, Dallas, TX 75230, USA
Diabetes Care 28:950-5. 2005..We further assessed the risk for hypoglycemia in a meta-analysis of controlled trials of a similar design for insulin glargine versus once- or twice-daily NPH insulin in adults with type 2 diabetes... - Repaglinide versus nateglinide monotherapy: a randomized, multicenter studyJulio Rosenstock
Dallas Diabetes and Endocrine Center, 7777 Forest Lane, Suite C618, Dallas, TX 75230, USA
Diabetes Care 27:1265-70. 2004..A randomized, parallel-group, open-label, multicenter 16-week clinical trial compared efficacy and safety of repaglinide monotherapy and nateglinide monotherapy in type 2 diabetic patients previously treated with diet and exercise... - Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosingJulio Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, USA
Diabetes Care 32:1880-6. 2009.... - Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trialJulio Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas 75230, USA
Ann Intern Med 143:549-58. 2005..Patients with type 2 diabetes who do not achieve glycemic control with oral agent therapy eventually require insulin... - Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) studyJ Rosenstock
Dallas Diabetes and Endocrine Center, Dallas, TX 75230, USA
Diabetes Obes Metab 8:49-57. 2006..To compare the efficacy, safety and tolerability of adding rosiglitazone (RSG) vs. sulphonylurea (SU) dose escalation in older type 2 diabetes mellitus (T2DM) patients inadequately controlled on SU therapy... - Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patientsJulio Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, 7777 Forest Lane, C 618, Dallas, TX 75230, USA
Diabetes Care 29:554-9. 2006..To evaluate the efficacy and safety of add-on insulin glargine versus rosiglitazone in insulin-naïve patients with type 2 diabetes inadequately controlled on dual oral therapy with sulfonylurea plus metformin... - Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulinJ Rosenstock
Dallas Diabetes and Endocrine Center, Texas 75230, USA
Diabetes Care 24:631-6. 2001..To determine the safety and efficacy of the long-acting analog insulin glargine compared with NPH insulin in patients with type 2 diabetes who were previously treated with insulin alone... - Management of type 2 diabetes mellitus in the elderly: special considerationsJ Rosenstock
Dallas Diabetes and Endocrine Center, Medical City Dallas, Texas 75230, USA
Drugs Aging 18:31-44. 2001..Optimal glycaemic control should be possible for every patient if treatment is individualised; however, strict glycaemic control may not be achievable in all patients or even desirable in many elderly patients... - Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trialJulio Rosenstock
Dallas Diabetes and Endo Research Center, 7777 Forest Lane, C618, Dallas, TX 75230, USA
Pain 110:628-38. 2004..Most adverse events were mild to moderate and did not result in withdrawal. Pregabalin was safe and effective in decreasing pain associated with DPN, and also improved mood, sleep disturbance, and quality of life... - Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator GroupJ Rosenstock
Dallas Diabetes and Endocrine Center, Texas 75230, USA
Diabetes Care 23:1137-42. 2000..It recently received approval from the Food and Drug Administration. The aim of this study was to evaluate 2 formulations of insulin glargine for safety and efficacy in the treatment of patients with type 1 diabetes... - Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetesJ Rosenstock
Dallas Diabetes and Endocrine Center, Dallas, TX, USA
Diabetes Obes Metab 9:175-85. 2007..The aim of this study was to compare efficacy and tolerability of initial combination therapy with vildagliptin/pioglitazone to component monotherapy... - A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetesP Raskin
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
Diabetes Care 24:1226-32. 2001..To determine the efficacy and safety of rosiglitazone (RSG) when added to insulin in the treatment of type 2 diabetic patients who are inadequately controlled on insulin monotherapy... - Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapyJ Rosenstock
Dallas Diabetes and Endocrine Center, Texas, USA
Int J Clin Pract 56:251-7. 2002..Pioglitazone treatment also provided significant benefit with respect to plasma HDL-C and triglyceride levels. Whether these lipid changes have an impact on overall diabetic complications remains to be determined... - Titration of inhaled human insulin (Exubera) in a treat-to-target regimen for patients with type 2 diabetesPriscilla A Hollander
Baylor University Medical Center, Dallas, Texas 75246, USA
Diabetes Technol Ther 12:185-91. 2010..New York, NY] [insulin human (recombinant DNA origin)] inhalation powder) in patients with type 2 diabetes inadequately controlled on combination oral antidiabetes agents (OADs)... - Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargineJulio Rosenstock
Dallas Diabetes and Endocrine Center, Texas, USA
Diabetes Technol Ther 11:S63-73. 2009..Cambridge, MA] and Eli Lilly and Company [Indianapolis, IN]; AIR is a registered trademark of Alkermes, Inc.), intensifying glargine via validated titration algorithms (IG), or adding AIR insulin while intensifying glargine (AIR + IG)... - Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trialAlan Garber
Baylor College of Medicine, Houston, TX, USA
Lancet 373:473-81. 2009..New treatments for type 2 diabetes mellitus are needed to retain insulin-glucose coupling and lower the risk of weight gain and hypoglycaemia. We aimed to investigate the safety and efficacy of liraglutide as monotherapy for this disorder... - Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetesJulio Rosenstock
Dallas Diabetes and Endocrine Center, Dallas, Texas, USA
Diabetes Care 27:1318-23. 2004.... - Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetesJulio Rosenstock
Dallas Diabetes and Endocrine Center, Dallas, Texas, USA
Diabetes Care 25:1529-33. 2002.... - Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyJulio Rosenstock
Dallas Diabetes and Endocrine Center, Dallas, Texas, USA
Clin Ther 28:1556-68. 2006..01). Sitagliptin was generally well tolerated, with no increased risk of hypoglycemia compared with placebo (2 vs 0 patients, respectively)... - Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose toleranceJulio Rosenstock
Dallas Diabetes and Endocrine Center, Dallas, Texas, USA
Diabetes Care 31:30-5. 2008..This study was conducted to determine the effects of vildagliptin on incretin hormone levels, islet function, and postprandial glucose control in subjects with impaired glucose tolerance (IGT)... - Insulin therapy: optimizing control in type 1 and type 2 diabetesJ Rosenstock
University of Texas Southwestern Medical Center at Dallas, Dallas Diabetes and Endocrine Center, Dallas, Texas, USA
Clin Cornerstone 4:50-64. 2001.... - The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapyJulio Rosenstock
Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, USA
Diabetes Care 33:1516-22. 2010..The efficacy and safety of the 11betaHSD1 inhibitor INCB13739 were assessed when added to ongoing metformin monotherapy in patients with type 2 diabetes exhibiting inadequate glycemic control (A1C 7-11%)... - Basal insulin supplementation in type 2 diabetes; refining the tacticsJulio Rosenstock
Dallas Diabetes and Endocrine Center, 7777 Forest Lane, Dallas, TX 75230, USA
Am J Med 116:10S-16S. 2004.... - Counterpoint: Inpatient glucose management: a premature call to arms?Silvio E Inzucchi
Dallas Diabetes and Endocrine Center, Medical City Dallas, 7777 Forest Lane, Suite C 618, Dallas, TX 75230, USA
Diabetes Care 28:976-9. 2005 - What are incretins, and how will they influence the management of type 2 diabetes?Lawrence Blonde
Ochsner Diabeed Clinical Research Unit, Department of Internal Medicine, Ochsner Clinic Foundation, 1514 Jefferson Hwy, New Orleans, LA 70121, USA
J Manag Care Pharm 12:S2-12; quiz S14-6. 2006..Novel incretin-based therapies currently available, and in late-stage development, are among those showing the greatest promise for addressing the unmet needs of traditional therapies... - Management of prediabetes: setting the stageJulio Rosenstock
Diabetes Obes Metab 9:1-2. 2007 - Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapyRichard E Pratley
Vermont College of Medicine, Burlington, USA
Diabetes Care 30:3017-22. 2007..The purpose of this study was to evaluate the efficacy and safety of vildagliptin in elderly patients with type 2 diabetes... - Effect of tesaglitazar, a dual PPARalpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trialBarry J Goldstein
Curr Med Res Opin 22:2575-90. 2006..0 mg and 3.0 mg doses limits conclusions about the efficacy of these doses. The 0.5 mg and 1.0 mg tesaglitazar doses were identified for further investigation... - Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trialBarry J Goldstein
Department of Medicine, Jefferson Medical College of Thomas Jefferson University, 349 Jefferson Alumni Hall, 1020 Locust Street, Philadelphia, PA 19107, USA
Curr Med Res Opin 22:2575-90. 2006..The Glucose and Lipid Assessment in Diabetes (GLAD) trial examined the dose-response relationship of the dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist tesaglitazar in type 2 diabetic patients... - Inhaled insulin: a novel route for insulin deliveryWilliam T Cefalu
University of Vermont College of Medicine, Burlington, VT, USA
Expert Opin Investig Drugs 11:687-91. 2002..The pharmacokinetics of inhaled insulin show a more physiological profile compared to conventional insulin; however, further studies to confirm long-term pulmonary safety and efficacy are needed... - Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimenJoseph C Cappelleri
Pfizer Inc, Global Research and Development, Groton, Connecticut 06340, USA
Clin Ther 24:552-64. 2002..It is unknown whether inhalation delivery of insulin improves patient satisfaction... - Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trialF Xavier Pi-Sunyer
Obesity Research Center, St Luke s Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, NY 10025, USA
JAMA 295:761-75. 2006..Rimonabant, a selective cannabinoid-1 receptor blocker, may reduce body weight and improve cardiometabolic risk factors in patients who are overweight or obese... - The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patientsMatthew C Riddle
Oregon Health and Science University, Portland, Oregon 97201, USA
Diabetes Care 26:3080-6. 2003..To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7% HbA(1c)... - Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse!Julio Rosenstock
Diabetes Care 30:2972-3. 2007 - Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargineSatish K Garg
Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
Endocr Pract 11:11-7. 2005..03). CONCLUSION: Better A1c reductions were obtained with premeal GLU, but postmeal administration of GLU was as safe and effective as premeal GLU or RHI in combination with insulin glargine and was not associated with weight gain... - Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylureaDavid M Kendall
International Diabetes Center and University of Minnesota, Minmneapolis, MN, USA
Diabetes Care 28:1083-91. 2005..This improvement in glycemic control was associated with no weight gain and was generally well tolerated... - Insulin glargine: commentary on the duration of action and lower risk of nocturnal hypoglycaemia in patients with diabetesJulio Rosenstock
Expert Opin Pharmacother 5:1-2; author reply 2-3. 2004 - Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapyVivian A Fonseca
Tulane University Health Sciences Center, New Orleans, Louisiana, USA
Diabetes Care 31:1479-84. 2008..This study tested the LDL cholesterol-lowering agent colesevelam HCl (colesevelam) as a potential novel treatment for improving glycemic control in patients with type 2 diabetes on sulfonylurea-based therapy... - Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patientsMark L Warren
Department of Endocrinology and Metabolism, Physicians East, PA, 1850 W Arlington Blvd, Greenville, NC 27834, USA
Diabetes Res Clin Pract 66:23-9. 2004..For some elderly type 2 diabetes patients, postprandial injection of BIAsp 30 may be an acceptable alternative to standard preprandial injection... - Insulin glulisine provides improved glycemic control in patients with type 2 diabetesGeorge Dailey
Scripps Clinic, 10666 North Torrey Pines Rd, La Jolla, CA 92037, USA
Diabetes Care 27:2363-8. 2004..Insulin glulisine is a novel analog of human insulin designed for use as a rapid-acting insulin. This study compared the safety and efficacy of glulisine with regular human insulin (RHI) in combination with NPH insulin... - Prevention of cardiovascular outcomes in type 2 diabetes mellitus: trials on the horizonJohn B Buse
Divisions of Endocrinology and General Medicine, Diabetes Care Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7110, USA
Endocrinol Metab Clin North Am 34:221-35. 2005.... - Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: can it offer both cardiovascular protection and beta-cell preservation?Hertzel C Gerstein
Division of Endocrinology and Metabolism and the Population Health Research Institute, Department of Medicine, McMaster University and Hamilton Health Sciences, Hamilton, ON L8N 3Z5, Canada
Endocrinol Metab Clin North Am 34:137-54. 2005..Mounting evidence suggests that insulin therapy may reduce risk for CV events while preserving beta-cell function, and several continuing long-term CV trials are testing these hypotheses explicitly...